

NYSE Data Project

Presented By

Alina Labatsevich

With focus on

Biotechnology Sector (VRTX®N)

How The Biotechnology sector(VRTX®N) Look Like Throughout 4 Years?

Profit and Loss Statement **VRTX**

	Historical			Assumptions		
	I					
	Year 1	Year 2	Year 3	Year 4	Year 5	Year 6
Revenue	\$ 1 527 042 000	\$ 1 211 975 000	\$ 580 415 000	\$ 1 032 336 000	\$ 1 049 951 825	\$ 1 130 383 210
COGS	\$ 279 885 000	\$ 130 277 000	\$ 60 987 000	\$ 124 512 000		
Gross Profit	\$ 1 247 157 000	\$ 1 081 698 000	\$ 519 428 000	\$ 907 824 000	\$ 914 386 265	\$ 873 879 766
Sales, General and Admin	\$ 432 681 000	\$ 356 188 000	\$ 305 409 000	\$ 376 575 000		
Operating Expenses	\$ -	\$ -	\$ -	\$ -		
Research and Development	\$ 765 905 000	\$ 882 097 000	\$ 855 506 000	\$ 995 922 000		
Total operating expensess	\$ 1 198 586 000	\$ 1 238 285 000	\$ 1 160 915 000	\$ 1 372 497 000		
Operating Profit	\$ 48 571 000	\$ -156 587 000	\$ -641 487 000	\$ -464 673 000	\$ -433 822 209	\$ 332 441 668

Profit and Loss Statement **REGN**

	Historical			Assumptions		
	Year 1	Year 2	Year 3	Year 4	Year 5	Year 6
Revenue	\$ 2 104 745 000	\$ 2 819 557 000	\$ 4 103 728 000	\$ 4 860 427 000	\$ 6 447 297 593	\$ 6 941 191 749
COGS	\$ 155 355 000	\$ 205 018 000	\$ 392 709 000	\$ 299 694 000		
Gross Profit	\$ 1 949 390 000	\$ 2 614 539 000	\$ 3 711 019 000	\$ 4 560 733 000	\$ 5 957 495 883	\$ 5 366 115 641
Sales, General and Admin	\$ 346 393 000	\$ 519 267 000	\$ 838 526 000	\$ 1 177 697 000		
Operating Expenses	\$ -	\$ -	\$ -	\$ -		
Research and Development	\$ 859 947 000	\$ 1 271 353 000	\$ 1 620 577 000	\$ 2 052 295 000		
Total operating expensess	\$ 1 206 340 000	\$ 1 790 620 000	\$ 2 459 103 000	\$ 3 229 992 000		
Operating Profit	\$ 743 050 000	\$ 823 919 000	\$ 1 251 916 000	\$ 1 330 741 000	\$ 1 973 050 922	\$ 2 041 379 719

VRTX	
Years	Operating Profit
Year 1	\$ 48 571 000
Year 2	\$ -156 587 000
Year 3	\$ -641 487 000
Year 4	\$ -464 673 000

REGN	
Years	Operating Profit
Year 1	\$ 743 050 000
Year 2	\$ 823 919 000
Year 3	\$ 1 251 916 000
Year 4	\$ 1 330 741 000

VRTX	
Mean	\$ -303 544 000
Standard Deviation	\$ 308 625 641
Minimum Value	\$ -641 487 000
First Quartile	\$ -508 876 500
Second Quartile (Median)	\$ -310 630 000
Third Quartile	\$ -105 297 500
Maximum Value	\$ 48 571 000
Range	\$ 690 058 000
Interquartile Range (IQR)	\$ 403 579 000

Difference

\$ -641 487 000

\$ 132 610 500

\$ 198 246 500

\$ 205 332 500

\$ 153 868 500

REGN	
Mean	\$ 1 037 406 500
Standard Deviation	\$ 296 806 399
Minimum Value	\$ 743 050 000
First Quartile	\$ 803 701 750
Second Quartile (Median)	\$ 1 037 917 500
Third Quartile	\$ 1 271 622 250
Maximum Value	\$ 1 330 741 000
Range	\$ 587 691 000
Interquartile Range (IQR)	\$ 467 920 500

Difference

\$ 743 050 000


\$ 60 651 750

\$ 234 215 750

\$ 233 704 750

\$ 59 118 750

How The Biotechnology sector(VRTX®N) Look Like Throughout 4 Years



In these charts, we can see the annual revenues for companies in 4 years in the Biotechnology.

The skewed for REGN sector is left skewed

Revenue Growth % REGN Base year 34% 46% 18%

Revenue Growth % VRTX Base year -21% -52% 78%

Reference

- Analytics with Spreadsheets (Masterschool) – Udacity

The mean total revenue for REGN (\$1037406500) was higher compared to mean total revenue for VRTX (\$-303544000). it looks like company REGN have a higher total revenue on average than VRTX.

The Median total revenue for REGN(\$1037917500) was higher compared to median total revenue for VRTX (\$-310630000).

The standard deviation of total revenue for VRTX(\$308625641) was higher compared to the standard deviation of total revenue for REGN(296806399).

"It appears that VRTX have less stable revenues as they change on average more than the average change (Standard Deviation) of REGN.

"The Range for VRTX Total Revenue at \$6900580000 is higher compared with The Range of Total Revenue for the REGN at only \$587691000. It looks like the VRTX have greater variability in the total revenues they receive because their range is more spread out."